{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:25:35Z","timestamp":1790771135647,"version":"4.1.0"},"reference-count":44,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Agency for Research","doi-asserted-by":"publisher","award":["ANR-11-LABX-0018-01"],"award-info":[{"award-number":["ANR-11-LABX-0018-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pays de la Loire Regional Council","award":["ANR-11-LABX-0018-01"],"award-info":[{"award-number":["ANR-11-LABX-0018-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The aim of this multicentric study was to prospectively compare 68Ga-DOTANOC PET\/CT versus somatostatin receptor scintigraphy (SRS) with SPECT\/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT\/CT, multiphasic CT scan and\/or liver MRI followed by 68Ga-DOTANOC PET\/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. 68Ga-DOTANOC PET\/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p &lt; 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p &lt; 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). 68Ga-DOTANOC PET\/CT had an impact on the therapeutic management of 41.9% (44\/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of 68Ga-DOTANOC PET\/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs.<\/jats:p>","DOI":"10.3390\/cancers15020513","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T04:31:32Z","timestamp":1673843492000},"page":"513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prospective Multicentric Assessment of 68Ga-DOTANOC PET\/CT in Grade 1-2 GEP-NET"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2278-0488","authenticated-orcid":false,"given":"Alexandre","family":"Lugat","sequence":"first","affiliation":[{"name":"Medical Oncology Department, CHU Nantes, 44000 Nantes, France"},{"name":"Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), University of Nantes, INSERM UMR 1232, 44000 Nantes, France"},{"name":"CHU Nantes, Nantes Universit\u00e9, M\u00e9decine Nucl\u00e9aire, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Frampas","sequence":"additional","affiliation":[{"name":"Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), University of Nantes, INSERM UMR 1232, 44000 Nantes, France"},{"name":"Central Department of Radiology and Medical Imaging, CHU Nantes, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Touchefeu","sequence":"additional","affiliation":[{"name":"Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), University of Nantes, INSERM UMR 1232, 44000 Nantes, France"},{"name":"The Enteric Nervous System in Gut and Brain Disorders, Universit\u00e9 de Nantes, INSERM, TENS, IMAD, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Miralli\u00e9","sequence":"additional","affiliation":[{"name":"Chirurgie Canc\u00e9rologique, Digestive et Endocrinienne, Institut des Maladies de l\u2019Appareil Digestif, CHU de Nantes, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblle Le","family":"Bras","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, L\u2019institut du Thorax, CHU Nantes, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Senellart","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, ICO Cancer Center, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Rauscher","sequence":"additional","affiliation":[{"name":"Pharmacy, ICO Cancer Center, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Fleury","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, ICO Cancer Center, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4903-0908","authenticated-orcid":false,"given":"Lo\u00efc","family":"Campion","sequence":"additional","affiliation":[{"name":"Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), University of Nantes, INSERM UMR 1232, 44000 Nantes, France"},{"name":"Biometrics, ICO Cancer Center, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rohmer","sequence":"additional","affiliation":[{"name":"Endocrinology Department, University Hospital, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier-Fran\u00e7ois","family":"Couturier","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University Hospital, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachida","family":"Lebtahi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Beaujon Hospital, 92110, Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rouzet","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, H\u00f4pital Bichat-Claude Bernard, AP-HP, 75018 Paris, France"},{"name":"Universit\u00e9 de Paris and Inserm U1148, 75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruszniewski","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Department of Gastroenterology-Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), 92110 Clichy, France"},{"name":"Universit\u00e9 de Paris, Centre of Research on Inflammation, INSERM U1149, 75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[{"name":"Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), University of Nantes, INSERM UMR 1232, 44000 Nantes, France"},{"name":"CHU Nantes, Nantes Universit\u00e9, M\u00e9decine Nucl\u00e9aire, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Bourgeois","sequence":"additional","affiliation":[{"name":"Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), University of Nantes, INSERM UMR 1232, 44000 Nantes, France"},{"name":"CHU Nantes, Nantes Universit\u00e9, M\u00e9decine Nucl\u00e9aire, 44000 Nantes, France"},{"name":"Groupement d\u2019Int\u00e9r\u00eat Public Arronax, 44800 Saint-Herblain, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ansquer","sequence":"additional","affiliation":[{"name":"Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), University of Nantes, INSERM UMR 1232, 44000 Nantes, France"},{"name":"CHU Nantes, Nantes Universit\u00e9, M\u00e9decine Nucl\u00e9aire, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000096997","article-title":"Evolution of the Diffuse Neuroendocrine System\u2013Clear Cells and Cloudy Origins","volume":"84","author":"Modlin","year":"2006","journal-title":"Neuroendocrinology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mce.2007.12.002","article-title":"Somatostatin, Cortistatin and Their Receptors in Tumours","volume":"286","author":"Volante","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0960-0760(92)90184-K","article-title":"Somatostatin Receptors in Human Cancer: Incidence, Characteristics, Functional Correlates and Clinical Implications","volume":"43","author":"Reubi","year":"1992","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","article-title":"Localisation of Endocrine-Related Tumours with Radioiodinated Analogue of Somatostatin","volume":"1","author":"Krenning","year":"1989","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/0016-5085(93)91066-Q","article-title":"Somatostatin-Receptor Imaging of Neuroendocrine Gastroenteropancreatic Tumors","volume":"105","author":"Fett","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin Receptor Scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-Octreotide: The Rotterdam Experience with More than 1000 Patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s002590050314","article-title":"Comparison of Somatostatin Receptor Imaging, Computed Tomography and Ultrasound in the Clinical Management of Neuroendocrine Gastro-Entero-Pancreatic Tumours","volume":"25","author":"Chiti","year":"1998","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in Patients with Neuroendocrine Tumours","volume":"34","author":"Buchmann","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","article-title":"111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden","volume":"60","author":"Hope","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2967\/jnumed.116.179234","article-title":"Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions","volume":"57","author":"Deroose","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0284185113496679","article-title":"Diagnostic Role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in Patients with Neuroendocrine Tumors: A Meta-Analysis","volume":"55","author":"Yang","year":"2014","journal-title":"Acta Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2967\/jnumed.112.111724","article-title":"Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within Patients with Gastroenteropancreatic Neuroendocrine Tumors","volume":"54","author":"Wild","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e19162","DOI":"10.1097\/MD.0000000000019162","article-title":"Impact of 68Ga-DOTATOC PET\/CT in Comparison to 111In-Octreotide SPECT\/CT in Management of Neuro-Endocrine Tumors","volume":"99","author":"Tolomeo","year":"2020","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/MPA.0000000000001625","article-title":"Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography\u2013Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors","volume":"49","author":"Ghobrial","year":"2020","journal-title":"Pancreas"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/MNM.0000000000000623","article-title":"The Role of 68Ga-DOTA-NOC PET\/CT in Evaluating Neuroendocrine Tumors: Real-World Experience from Two Large Neuroendocrine Tumor Centers","volume":"38","author":"Haidar","year":"2017","journal-title":"Nucl. Med. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2967\/jnumed.115.163865","article-title":"Safety and Efficacy of 68Ga-DOTATATE PET\/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors","volume":"57","author":"Deppen","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.21037\/jgo.2016.01.06","article-title":"Ga-68 DOTANOC PET\/CT Imaging in Detection of Primary Site in Patients with Metastatic Neuroendocrine Tumours of Unknown Origin and Its Impact on Clinical Decision Making: Experience from a Tertiary Care Centre in India","volume":"7","author":"Pruthi","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","article-title":"68Ga-DOTA-NOC PET\/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan\u00ae)","volume":"13","author":"Krausz","year":"2011","journal-title":"Mol. Imaging Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","article-title":"Detection of Unknown Primary Neuroendocrine Tumours (CUP-NET) Using (68)Ga-DOTA-NOC Receptor PET\/CT","volume":"37","author":"Prasad","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","article-title":"Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the Detection of Gastro-Entero-Pancreatic and Lung Neuro-Endocrine Tumours","volume":"35","author":"Ambrosini","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s12020-019-02098-2","article-title":"68Ga-DOTATOC PET\/CT in Detecting Neuroendocrine Tumours Responsible for Initial or Recurrent Paraneoplastic Cushing\u2019s Syndrome","volume":"67","author":"Nataf","year":"2020","journal-title":"Endocrine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00259-011-1935-5","article-title":"Cost Comparison of 111In-DTPA-Octreotide Scintigraphy and 68Ga-DOTATOC PET\/CT for Staging Enteropancreatic Neuroendocrine Tumours","volume":"39","author":"Schreiter","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO Classification of Tumours of the Digestive System","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s11307-018-1195-x","article-title":"Optimization of a Labeling and Kit Preparation Method for Ga-68 Labeled DOTATATE, Using Cation Exchange Resin Purified Ga-68 Eluates Obtained from a Tin Dioxide 68Ge\/68Ga Generator","volume":"20","author":"Prince","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2217\/fon.14.285","article-title":"Pancreatic Neuroendocrine Tumors: A Review","volume":"11","author":"Young","year":"2015","journal-title":"Future Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis","volume":"57","author":"Deppen","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective Study of 68Ga-DOTATATE Positron Emission Tomography\/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites","volume":"34","author":"Sadowski","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","article-title":"68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis","volume":"58","author":"Graham","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00259-009-1349-9","article-title":"68Ga-DOTA-NOC PET\/CT in Comparison with CT for the Detection of Bone Metastasis in Patients with Neuroendocrine Tumours","volume":"37","author":"Ambrosini","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00268-017-4364-1","article-title":"Preoperative 68Ga-DOTA-Somatostatin Analog-PET\/CT Hybrid Imaging Increases Detection Rate of Intra-Abdominal Small Intestinal Neuroendocrine Tumor Lesions","volume":"42","author":"Montan","year":"2018","journal-title":"World J. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nappo, G., Funel, N., Giudici, S., Spaggiari, P., Capretti, G., Carrara, S., Pepe, G., and Zerbi, A. (2020). Pancreatic Serous Cystoadenoma (CSA) Showing Increased Tracer Uptake at 68-GaDOTA-Peptide Positron Emission Tomography (68Ga-DOTA-Peptide PET-CT): A Case Report. BMC Surg., 20.","DOI":"10.1186\/s12893-020-01004-2"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT Imaging of Neuroendocrine Neoplasms with 68Ga-DOTA-Conjugated Somatostatin Receptor Targeting Peptides and 18F\u2013DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","article-title":"Procedure Guidelines for PET\/CT Tumour Imaging with 68Ga-DOTA-Conjugated Peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE","volume":"37","author":"Virgolini","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.109.071712","article-title":"68Ga-DOTANOC PET\/CT Clinical Impact in Patients with Neuroendocrine Tumors","volume":"51","author":"Ambrosini","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000265561","article-title":"Impact of Multiphase 68Ga-DOTATOC-PET\/CT on Therapy Management in Patients with Neuroendocrine Tumors","volume":"91","author":"Ruf","year":"2010","journal-title":"Neuroendocrinology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The Impact of 68Ga-DOTATOC Positron Emission Tomography\/Computed Tomography on the Multimodal Management of Patients with Neuroendocrine Tumors","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2214\/AJR.11.7298","article-title":"Gallium-68-DOTA-NOC PET\/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study","volume":"197","author":"Naswa","year":"2011","journal-title":"Am. J. Roentgenol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High Management Impact of Ga-68 DOTATATE (GaTate) PET\/CT for Imaging Neuroendocrine and Other Somatostatin Expressing Tumours: Management Impact of GaTate PET\/CT","volume":"56","author":"Hofman","year":"2012","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The Impact of 68Ga-DOTATATE PET\/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom","volume":"57","author":"Skoura","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13139-017-0496-3","article-title":"Impact of 68Ga-DOTA-Peptide PET\/CT on the Management of Gastrointestinal Neuroendocrine Tumour (GI-NET): Malaysian National Referral Centre Experience","volume":"52","author":"Tan","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jso.25812","article-title":"Impact of Initial Imaging with Gallium-68 Dotatate PET\/CT on Diagnosis and Management of Patients with Neuroendocrine Tumors","volume":"121","author":"Crown","year":"2020","journal-title":"J. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:55Z","timestamp":1760119555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15020513"],"URL":"https:\/\/doi.org\/10.3390\/cancers15020513","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]}}}